Table 4.

Myeloid and monocytic dyspoiesis detected by flow cytometry



Patient group
Flow cytometric abnormality
MDS (n = 115)
Aplastic anemia (n = 26)
Nonhematopoietic malignancies (n = 15)
Hodgkin disease (n = 26)
Bone marrow transplant donors with cytopenias (n = 37)
All non-MDS subjects (n = 104)
Abnormal myeloblasts, no. (%)   72 (62)   0 (0)*  0 (0)*  0 (0)*  1 (3)*  1 (1)* 
Maturing myeloid        
Abnormal granularity   9 (8)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)* 
Abnormal decrease CD45   4 (3)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Abnormal relationship CD13/CD16   27 (23)   3 (12)   0 (0)*  3 (12)   6 (16)   12 (12)* 
Abnormal relationships        
HLA-DR/CD11b   6 (5)   0 (0)   0 (0)   1 (4)   1 (3)   2 (2)  
Asynchronous shift to the left   26 (23)   0 (0)*  0 (0)*  0 (0)*  0 (0)*  0 (0)* 
Presence of CD56   18 (16)   1 (4)   1 (7)   6 (23)   0 (0)*  8 (8)  
Lack of CD33   6 (5)   1 (4)   0 (0)   0 (0)   3 (8)   4 (4)  
Presence of CD34   7 (6)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)* 
Presence of lymphoid antigens   4 (3)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Monocytes        
Abnormal granularity   1 (1)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Lack of CD13 or CD16   1 (1)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Abnormal relationship HLA-DR/CD11b   5 (4)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Presence of CD56   19 (17)   0 (0)*  0 (0)   3 (12)   0 (0)*  3 (3)* 
Lack of CD33 or CD14   3 (3)   0 (0)   0 (0)   0 (0)   0 (0)*  0 (0)  
Presence of CD34   14 (12)   0 (0)   0 (0)   0 (0)   0 (0)*  0 (0)* 
Presence of lymphoid antigens   4 (3)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Abnormal L/M ratio   38 (33)   19 (73)  1 (7)*  0 (0)*  1 (3)*  21 (20)* 
Abnormal cytogenetics
 
71 (62)
 
0 (0)*
 
0 (0)*
 
1 (4)*
 
0 (0)*
 
1 (1)*
 


Patient group
Flow cytometric abnormality
MDS (n = 115)
Aplastic anemia (n = 26)
Nonhematopoietic malignancies (n = 15)
Hodgkin disease (n = 26)
Bone marrow transplant donors with cytopenias (n = 37)
All non-MDS subjects (n = 104)
Abnormal myeloblasts, no. (%)   72 (62)   0 (0)*  0 (0)*  0 (0)*  1 (3)*  1 (1)* 
Maturing myeloid        
Abnormal granularity   9 (8)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)* 
Abnormal decrease CD45   4 (3)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Abnormal relationship CD13/CD16   27 (23)   3 (12)   0 (0)*  3 (12)   6 (16)   12 (12)* 
Abnormal relationships        
HLA-DR/CD11b   6 (5)   0 (0)   0 (0)   1 (4)   1 (3)   2 (2)  
Asynchronous shift to the left   26 (23)   0 (0)*  0 (0)*  0 (0)*  0 (0)*  0 (0)* 
Presence of CD56   18 (16)   1 (4)   1 (7)   6 (23)   0 (0)*  8 (8)  
Lack of CD33   6 (5)   1 (4)   0 (0)   0 (0)   3 (8)   4 (4)  
Presence of CD34   7 (6)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)* 
Presence of lymphoid antigens   4 (3)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Monocytes        
Abnormal granularity   1 (1)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Lack of CD13 or CD16   1 (1)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Abnormal relationship HLA-DR/CD11b   5 (4)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Presence of CD56   19 (17)   0 (0)*  0 (0)   3 (12)   0 (0)*  3 (3)* 
Lack of CD33 or CD14   3 (3)   0 (0)   0 (0)   0 (0)   0 (0)*  0 (0)  
Presence of CD34   14 (12)   0 (0)   0 (0)   0 (0)   0 (0)*  0 (0)* 
Presence of lymphoid antigens   4 (3)   0 (0)   0 (0)   0 (0)   0 (0)   0 (0)  
Abnormal L/M ratio   38 (33)   19 (73)  1 (7)*  0 (0)*  1 (3)*  21 (20)* 
Abnormal cytogenetics
 
71 (62)
 
0 (0)*
 
0 (0)*
 
1 (4)*
 
0 (0)*
 
1 (1)*
 

The data field shows the number with percentage in parentheses.

*

Number of abnormalities are significantly lower than MDS patients (P of a 2-sided Fisher exact test < .05).

Number of abnormalities is significantly higher than MDS patients (P of a 2-sided Fisher exact test < .05).

One patient missing cytogenetic data.

or Create an Account

Close Modal
Close Modal